Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

A Turning Point for ASML? UBS Upgrade Sparks Optimism for the Chip Sector Giant

Robert Sasse by Robert Sasse
September 5, 2025
in Analysis, European Markets, Semiconductors, Turnaround
0
ASML Stock
0
SHARES
189
VIEWS
Share on FacebookShare on Twitter

After navigating a challenging period, Dutch semiconductor equipment manufacturer ASML is showing signs of a potential recovery. In a notable shift, UBS has upgraded its rating on the company’s shares from “Neutral” to “Buy,” a move that follows a year where the stock declined by 20%. This bullish stance from the Swiss bank, which arrives amid lingering skepticism from other analysts, suggests the worst of the downturn may be over.

The upgrade is anchored on the belief that all known headwinds are now fully reflected in the share price. According to UBS analyst Francois-Xavier Bouvignies, concerns over weaker demand for lithography systems and ongoing uncertainties related to the Chinese market are already priced in.

UBS has set a new price target of 750 euros, a significant increase from its previous target of 660 euros. The bank’s forward-looking analysis is particularly striking, as it forecasts that ASML will achieve annual profit growth of 20 percent between 2026 and 2030. This projected acceleration is tied to imminent technological advancements in the chip industry.

Should investors sell immediately? Or is it worth buying ASML?

Two key developments are expected to be major catalysts. First, the new A14 processor node from TSMC is anticipated to drive renewed demand for ASML’s extreme ultraviolet (EUV) lithography systems. Second, the company’s groundbreaking next-generation High-NA EUV technology is on the verge of a commercial breakthrough. By the end of the decade, these advanced machines could contribute 15 to 20 percent of total company revenue, highlighting the immense growth potential for this monopolist in cutting-edge chip manufacturing.

However, this optimistic view is not universally shared. Other financial institutions have recently expressed caution. On September 2, Bank of America reduced its price target, citing macroeconomic uncertainties and potential tariff risks, with particular concern over sluggish demand from China. Similarly, both Erste Group and Freedom Broker have recently downgraded their ratings to “Hold.”

The upcoming quarterly report on October 15 is poised to be a critical test for these competing viewpoints. When ASML releases its third-quarter earnings, it will provide crucial insights into its current order book. While company management has thus far reaffirmed its full-year revenue guidance of 30 to 35 billion euros, investors are expected to scrutinize every detail of the report for clues about the company’s trajectory amidst conflicting market signals.

Ad

ASML Stock: Buy or Sell?! New ASML Analysis from February 7 delivers the answer:

The latest ASML figures speak for themselves: Urgent action needed for ASML investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

ASML: Buy or sell? Read more here...

Tags: ASML
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
AMD Stock

AMD's High-Stakes Balancing Act in the AI Boom

Apple Stock

Apple Stock Receives Major Boost from Court Victory and Emerging Market Surge

BioNTech Stock

BioNTech Achieves Major Oncology Breakthrough with Phase 3 Cancer Trial Success

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com